Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAP2 | P11137 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117028 | 0.86 | NGFR (0.40) | NPSR1RAD52BLMCYP1A2CYP2C9 | |
| SCHEMBL5121688 | 0.83 | SPR (0.39) | NPSR1RAD52BLMTDP1CYP1A2 | |
| SCHEMBL5122341 | 0.82 | BLM (0.38) | NPSR1RAD52BLMTDP1CYP1A2 | |
| SCHEMBL2983431 | 0.81 | MAP2 (0.51) | HTR6MAP2GAAKDM4E | |
| SCHEMBL7079051 | 0.80 | SPR (0.37) | NPSR1RAD52BLMTDP1CYP1A2 | |
| SCHEMBL5773017 | 0.80 | KDM4E (0.34) | NPSR1RAD52BLMHSD17B10MAP2 | |
| SCHEMBL4292563 | 0.80 | HTR6 (0.62) | NPSR1RAD52BLMTDP1CYP1A2 | |
| SCHEMBL6783853 | 0.79 | KDM4E (0.40) | NPSR1RAD52BLMTDP1CYP1A2 | |
| SCHEMBL5108567 | 0.75 | RAD52 (0.36) | NPSR1RAD52BLMTDP1CYP1A2 | |
| SCHEMBL5109529 | 0.75 | MAPK1 (0.36) | MAPK1MAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | claimed |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-07-14 | — | — | US | claimed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1301487-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2006-11-22 | — | — | EP | disclosed |
| EP-1631554-A2 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-07-14 | — | — | US | disclosed |
| WO-2004108687-A2 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040224955-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-11-11 | — | — | US | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | EIF2AK2, MAVS, NSUN3 | NPSR1 1985/4885RAD52 2122/4885BLM 438/4885 |
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | NPSR1 1532/4885RAD52 2371/4885BLM 1873/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | NPSR1 959/4885RAD52 2672/4885BLM 3226/4885 |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | EIF2AK2, MAVS, NSUN3 | NPSR1 1985/4885RAD52 2122/4885BLM 438/4885 |
| US-20040224955-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | NPSR1 1532/4885RAD52 2371/4885BLM 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.